X-38352591-C-A
Variant summary
Our verdict is Likely pathogenic. Variant got 9 ACMG points: 10P and 1B. PM2PP5_Very_StrongBP4
The NM_001407092.1(OTC):c.-79-27C>A variant causes a intron change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.00000336 in 595,258 control chromosomes in the GnomAD database, with no homozygous occurrence. There are 1 hemizygotes in GnomAD. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Pathogenic (★★).
Frequency
Consequence
NM_001407092.1 intron
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Likely_pathogenic. Variant got 9 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
OTC | NM_001407092.1 | c.-79-27C>A | intron_variant | Intron 2 of 11 | NP_001394021.1 | |||
OTC | NM_000531.6 | c.-106C>A | upstream_gene_variant | ENST00000039007.5 | NP_000522.3 | |||
OTC | XM_017029556.2 | c.-106C>A | upstream_gene_variant | XP_016885045.1 |
Ensembl
Frequencies
GnomAD3 genomes AF: 0.00000895 AC: 1AN: 111786Hom.: 0 Cov.: 22 AF XY: 0.00 AC XY: 0AN XY: 33946
GnomAD4 exome AF: 0.00000207 AC: 1AN: 483418Hom.: 0 Cov.: 7 AF XY: 0.00000642 AC XY: 1AN XY: 155650
GnomAD4 genome AF: 0.00000894 AC: 1AN: 111840Hom.: 0 Cov.: 22 AF XY: 0.00 AC XY: 0AN XY: 34010
ClinVar
Submissions by phenotype
Ornithine carbamoyltransferase deficiency Pathogenic:3
The patient had clinical and biochemical symptoms of OTC deficiency, and no disease causing sequence variants in the OTC coding sequence and canonical splice sites. Functional testing in cultured cells indicates reduced expression of reporter gene. -
This variant occurs in a non-coding region of the OTC gene. It does not change the encoded amino acid sequence of the OTC protein. The frequency data for this variant in the population databases is considered unreliable, as metrics indicate insufficient coverage at this position in the gnomAD database. This variant has been observed in individual(s) with ornithine transcarbamylase deficiency (PMID: 29282796, 35605046; Invitae). It has also been observed to segregate with disease in related individuals. ClinVar contains an entry for this variant (Variation ID: 487338). Algorithms developed to predict the effect of variants on protein structure and function are not available or were not evaluated for this variant. Experimental studies have shown that this variant affects OTC function (PMID: 29282796, 35605046). For these reasons, this variant has been classified as Pathogenic. -
The c.-106C>A variant in the OTC gene is located in the 5'UTR. This variant has been observed in multiple individuals with late-onset ornithine transcarbamylase deficiency (PMID: 29282796, 35605046, 35822098). This variant has been reported as a common ancestral allele in a large Utahn kinship (PMID: 35605046; https://www.janewrightearlotc.com/). This variant is rare in the gnomAD population database. This variant is located immediately adjacent to the HNF4 transcription factor binding site and functional studies have shown that this variant affects HNF4 binding. In HepG2 cells transfected with c.-106C>A plasmid, the relative lucierase actiivty was lower as compared to wild typer promoter sequence containing plasmid. Therefore, the c.-106C>A variant in OTC gene is classified as pathogenic for late-onset OTC deficiency. ACMG variant classification evidence codes: PS4+PS3+PP4+PP1 -
not provided Pathogenic:2
The OTC c.-106C>A variant (rs749748052; ClinVar Variation ID: 487338) occurs at a moderately conserved nucleotide located in the 5' untranslated region of the OTC gene and is localized in a HNF4a transcription factor binding site (Luksan 2014). In vitro transfection of reporter constructs harboring c.-106C>A into liver-derived cell lines demonstrate mild to moderate reduction in OTC expression (Han 2022, Jang 2018). This variant is reported in a single female individual in the 1000 Genomes Project (1/3775 alleles) but is absent from the Genome Aggregation Database, indicating it is not a common polymorphism. It has been described in multiple males affected with late-onset OTC deficiency and in several heterozygotes with positive allopurinol test results (Finkelstein 1990, Jang 2018, Hertzog 2022, Han 2022). In testing performed both in published studies and at ARUP Laboratories, this variant has been identified in multiple hemizygotes from a large, multigenerational kindred separated by many meioses (Finkelstein 1990, Jang 2018). Although this variant has also been observed in multiple asymptomatic male relatives (Jang 2018; ARUP Laboratories), since c.-106C>A is located in a regulatory site, it is likely that hemizygotes are less susceptible to stressors precipitating a hyperammonemic crisis than patients harboring pathogenic coding sequence variants. Based on available information, this variant is considered to be pathogenic for late onset OTC with incomplete penetrance. References: Finkelstein JE et al. Late-onset ornithine transcarbamylase deficiency in male patients. J Pediatr. 1990 Dec;117(6):897-902. PMID: 2246687. Han ST et al. A promoter variant in the OTC gene associated with late and variable age of onset hyperammonemia. J Inherit Metab Dis. 2022 Jul;45(4):710-718. PMID: 35605046. Hertzog A et al. A serendipitous journey to a promoter variant: The c.-106C>A variant and its role in late-onset ornithine transcarbamylase deficiency. JIMD Rep. 2022 Apr 12;63(4):271-275. PMID: 35822098. Jang Y et al. Disease-causing mutations in the promoter and enhancer of the ornithine transcarbamylase gene. Hum Mutat. 2018 Apr;39(4):527-536. PMID: 29282796. Luksan O et al. HNF-4alpha regulates expression of human ornithin carbamoyltransferase through interaction with two positive cis-acting regulatory elements located in the proximal promoter. Folia Biol (Praha). 2014;60(3):133-43. PMID: 25056436. -
Observed in hemizygous state in two individuals with late onset OTC deficiency; also reported in an asymptomatic adult male whose brother died from hyperammonemic encephalopathy and suspected OTCD; segregation studies for this variant in the affected brother were not possible (PMID: 29282796); Published functional studies demonstrate a damaging effect as the variant was shown to reduce promoter activity to approximately 10% or 27% of wildtype in absence or presence of enhancer; authors concluded that the mild effect of this variant was the reason for the late onset and incomplete penetrance (PMID: 35605046); No data available from control populations to assess the frequency of this variant; Nucleotide substitution has no predicted effect on splicing and is not conserved across species; This variant is associated with the following publications: (PMID: 35605046, Sonier[article]2022, 35822098, 35734906, 29282796) -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at